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Introduction {#sec006}
============

Hyperglycemia is a well-described complication following solid organ transplantation \[[@pone.0142363.ref001]--[@pone.0142363.ref003]\]. Among patients without a prior history of diabetes mellitus (DM), hyperglycemia that either persists after transplant, or which resolves but later recurs and persists, is termed new onset diabetes after transplant (NODAT). Hyperglycemia and NODAT are strong predictors of graft failure and cardiovascular mortality occurring commonly after solid organ transplant \[[@pone.0142363.ref001]--[@pone.0142363.ref003]\]. The occurrence of hyperglycemia or development of NODAT have been attributed to many factors, including (1) immunosuppressive drugs and their diabetogenic effects, (2) other demographic and medical-related risk factors, and (3) inpatient hyperglycemic conditions.

Regarding the first factor, [Table 1](#pone.0142363.t001){ref-type="table"} summarizes studies on the diabetogenic effect of anti-rejection agents (e.g., tacrolimus, sirolimus, cyclosporine, glucocorticoids, and steroid) with respect to different solid organ transplantations (e.g., kidney, liver, and pancreas). The main insights from this literature are related to: (1) the efficacy of a drug in preventing organ rejection while imposing less risk for hyperglycemia or NODAT, (2) the relative benefits/side effects of two or more drugs when compared with each other, and (3) the potentials of drugs when switching from one therapy to another.

10.1371/journal.pone.0142363.t001

###### Classification of literature based on diabetogenic effect of immunosuppressive drugs.
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  **Drug Type**     **Organ Type**    **Selected References**
  ----------------- ----------------- ----------------------------------------------------------------------------
  Tacrolimus        Kidney/Liver      \[[@pone.0142363.ref004]--[@pone.0142363.ref018]\]
  Sirolimus         Kidney/Liver      \[[@pone.0142363.ref017], [@pone.0142363.ref019]--[@pone.0142363.ref026]\]
  Cyclosporine      Kidney            \[[@pone.0142363.ref018], [@pone.0142363.ref027]--[@pone.0142363.ref037]\]
  Glucocorticoids   Kidney/Pancreas   \[[@pone.0142363.ref018], [@pone.0142363.ref038]--[@pone.0142363.ref044]\]
  Steroid           Kidney/Pancreas   \[[@pone.0142363.ref045]--[@pone.0142363.ref048]\]

In addition to immunosuppressive drugs, the literature has analyzed other demographic or medical-related risk factors to establish possible statistically significant associations with hyperglycemia and NODAT ([Table 2](#pone.0142363.t002){ref-type="table"}). The majority of the literature in this stream attempts to (1) derive associations between risk factor(s) and a continuous variable (linear regression models) that represents hyperglycemia/NODAT status (e.g., blood glucose level measured by hemoglobin A1c and fasting plasma glucose tests), (2) demonstrate the same effect for a categorical variable (i.e., whether a patient suffers from hyperglycemia or not, at a specific point of time) by applying logistic regression models, or (3) discuss the probability of survival from hyperglycemia/NODAT at a single point of time (Cox regression models).

10.1371/journal.pone.0142363.t002

###### Classification of literature based on the impact of risk factors on hyperglycemia and NODAT.
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  **Risk Factor**     **Organ Type**   **Selected References**
  ------------------- ---------------- ----------------------------------------------------------------------------------------------------------------------------------------------------
  Age                 Kidney/Liver     \[[@pone.0142363.ref049]--[@pone.0142363.ref057]\]
  Gender              Kidney/Liver     \[[@pone.0142363.ref053], [@pone.0142363.ref054], [@pone.0142363.ref057]--[@pone.0142363.ref062]\]
  Race/Ethnicity      Kidney           \[[@pone.0142363.ref049], [@pone.0142363.ref052], [@pone.0142363.ref054], [@pone.0142363.ref057], [@pone.0142363.ref063], [@pone.0142363.ref064]\]
  BMI                 Kidney/Liver     \[[@pone.0142363.ref049]--[@pone.0142363.ref051], [@pone.0142363.ref053]--[@pone.0142363.ref057], [@pone.0142363.ref064]\]
  Cadaveric organ     Kidney/Liver     \[[@pone.0142363.ref050], [@pone.0142363.ref051], [@pone.0142363.ref053]--[@pone.0142363.ref055], [@pone.0142363.ref057]\]
  Hepatitis C Virus   Kidney/Liver     \[[@pone.0142363.ref049], [@pone.0142363.ref051], [@pone.0142363.ref053], [@pone.0142363.ref055], [@pone.0142363.ref057], [@pone.0142363.ref064]\]
  Hypertension        Kidney           \[[@pone.0142363.ref052], [@pone.0142363.ref055], [@pone.0142363.ref064]--[@pone.0142363.ref066]\]
  Diabetes History    Kidney           \[[@pone.0142363.ref049], [@pone.0142363.ref053], [@pone.0142363.ref057], [@pone.0142363.ref064], [@pone.0142363.ref066]\]

Furthermore, recent evidence indicates that hyperglycemia occurring in the immediate post-transplant period (i.e., during the post-operative hospital stay) is also associated with NODAT \[[@pone.0142363.ref067], [@pone.0142363.ref068]\].

In spite of all these efforts, none of these factors (immunosuppressive drugs and their diabetogenic effects, demographic and medical-related risk factors, and inpatient hyperglycemic conditions) have been analyzed with respect to the time course of post-transplant complications. Specifically, one critical aspect that is overlooked by the literature is an understanding and analysis of *remitting and relapsing* hyperglycemia in post-solid organ transplant recipients. Such an understanding can be critical because (1) the insights gained can be quite different from those previously known for the incidence of hyperglycemia and (2) these insights can be extended to other chronic diseases with the possibility of remitting and relapsing, such as cancer and multiple sclerosis. To the best of our knowledge, this is the first study analyzing the first and recurrent incidence of hyperglycemia. In particular, utilizing a population of renal transplant recipients who had no history of DM before transplantation, we undertake a set of analyses to determine which contributing factors are significantly associated with the first incidence, and which ones are significantly associated with the recurrent incidence.

Materials and Methods {#sec007}
=====================

Study Cohort {#sec008}
------------

After obtaining Mayo Clinic Institutional Review Board (Mayo Clinic IRB) approval (Continuing Review \#: PR13-004295-01) and written informed consent from all participating patients, this study conducts an analysis of 292 patients who underwent a renal transplant between 1999 and 2006 in Mayo Clinic Arizona, and who had no history of DM prior to surgery. Briefly, all patients were monitored at the time of transplant as well as month 1, 4, and 12 post-transplant. The available data included (1) demographic data such as age, race, and gender, (2) baseline patient characteristics including body mass index (BMI), blood pressure (BP), total cholesterol (Chol), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), uric acid (UA), and triglyceride (TG), (3) type of immunosuppressive drugs and diabetes medications that were used by the patients, (4) trough level of tacrolimus (as the main immunosuppressive drug used in this study), and (5) results of fasting plasma glucose (FPG) and Hemoglobin A1c (HbA1c) tests as measures of glycemic control. All major abbreviations used in this study are explained in [Table 3](#pone.0142363.t003){ref-type="table"}.

10.1371/journal.pone.0142363.t003

###### Description of abbreviations used in this study.
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  **Abbreviation**   **Description**
  ------------------ --------------------------------------
  HG                 Hyperglycemia
  FPG                Fasting plasma glucose
  HbA1c              Hemoglobin A1c
  *C* ~0~            Trough level of tacrolimus
  BMI                Body mass index
  BP                 Blood pressure
  Chol               Total cholesterol
  HDL                High-density lipoprotein cholesterol
  LDL                Low-density lipoprotein cholesterol
  TG                 Triglyceride
  UA                 Uric acid

Definitions {#sec009}
-----------

NODAT was defined as HbA1c ≥ 6.5%, or FPG ≥ 126 mg/dL, or the requirement of diabetes medications (e.g., insulin or oral agent) after patient discharge from hospital \[[@pone.0142363.ref067], [@pone.0142363.ref068]\]. We apply this criteria to determine the incidence of post-transplant hyperglycemia, which may happen just once or for multiple times (recurrent). We refer to either of these conditions as instances of *remitting and relapsing* hyperglycemia.

Statistical Methods {#sec010}
-------------------

We now explain the statistical inference methods we employed to analyze the effects of immunosuppressive drugs, the corresponding risk factors, and the inpatient period conditions on the first and recurrent incidence of post-transplant hyperglycemia. The statistical models used were: (i) The Cox regression model with time-dependent covariates, which measures the *proportional hazard* imposed on the response variable (hyperglycemia incidence) by covariates that change over time. For example, the BMI of a patient may change as his/her weight changes (Chol, HDL, and LDL are some other examples of such covariates). As another example, whether the patient uses an immunosuppressive drug at a specific time or not can be considered as a time-dependent covariate. Therefore, we sought to fully comprehend the effect of these changing behaviors on the recurrent incidence of hyperglycemia. (ii) Cox regression model with time-independent covariates, which measures the proportional hazard imposed on the response variable (the first incidence of hyperglycemia) by covariates at the time of the first incidence of hyperglycemia. (iii) Kaplan-Meier survival analysis to characterize the cumulative probability of experiencing hyperglycemia over time.

The statistical analyses also include *multiple imputations by chained equations* (MICE) \[[@pone.0142363.ref069]\], which we used to replace some missing data (with the prevalence of less than 10% in our data set) with validated values. We conducted all statistical analyses by using the R computing package.

Results {#sec011}
=======

Demographic and Baseline Characteristics of Patients {#sec012}
----------------------------------------------------

Among 407 patients in the study cohort, there were 115 patients with the history of diabetes. The remaining 292 patients had no indication of diabetes prior to or at the time of their transplants. The average age of patients who had no diabetes before transplant was 49.7 years, while those who had diabetes before had the average age of 56. [Table 4](#pone.0142363.t004){ref-type="table"} summarizes the demographic data along with some other baseline characteristics of patients.

10.1371/journal.pone.0142363.t004

###### Demographic and baseline characteristics of patients at the time of transplant.
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  **Characteristics**                                     **Diabetes History (n = 115)**                      **No Diabetes History (n = 292)**
  ------------------------------------------------------- --------------------------------------------------- -----------------------------------
  Age (year)                                              56.0 ± 10.4^[a](#t004fn001){ref-type="table-fn"}^   49.7 ± 14.6
  Gender: Male (%)                                        61.74                                               56.16
  Race: White^[b](#t004fn002){ref-type="table-fn"}^ (%)   59.13                                               75.34
  BMI (kg/m^2^)                                           28.7 ± 5.4                                          27.0 ± 5.6
  Donor: Live^[c](#t004fn003){ref-type="table-fn"}^ (%)   52.17                                               67.47
  Pre-transplant FPG (mg/dL)                              143.8 ± 52.3                                        92.8 ± 11.3
  Pre-transplant HbA1c (%)                                6.9 ± 1.5                                           5.5 ± 0.3
  Pre-transplant UA (mg/dL)                               6.3 ± 2.3                                           6.6 ± 2.1
  Pre-transplant Chol(mg/dL)                              183.0 ± 47.4                                        181.9 ± 46.0
  Pre-transplant HDL (mg/dL)                              50.6 ± 16.0                                         50.6 ± 16.0
  Pre-transplant LDL (mg/dL)                              94.2 ± 33.0                                         93.9 ± 34.8
  Pre-transplant TG (mg/dL)                               191.2 ± 94.7                                        179.0 ± 87.7

^a^ mean ± standard deviation,

^b^ versus non-white (including Native American, Hispanic, and Black races),

^c^ versus cadaveric.

Incidence of Hyperglycemia {#sec013}
--------------------------

Regarding the definition of remitting and relapsing hyperglycemia, [Table 5](#pone.0142363.t005){ref-type="table"} summarizes different hyperglycemic states that can occur after renal transplantation. Therefore, 79 (27.06%) patients experienced *remitting and relapsing* post-transplant hyperglycemia (and hence the hyperglycemia for the first time). Among these patients, 19+3+1+24 = 47 patients experienced hyperglycemia multiple times, while 20+11+1 = 32 had it just once. As an example of the potential remitting and relapsing nature of post-transplant hyperglycemia, there are 11 patients who developed hyperglycemia at 4 months, which resolved at 12 months.

10.1371/journal.pone.0142363.t005

###### Percentage of patients satisfying the criteria.
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  **Time**             **Having the criteria?**                                                                        
  -------------------- -------------------------- ----------- ----------- ---------- ----------- ---------- ---------- -----------
  Month 1              No                         Yes         No          No         Yes         Yes        No         Yes
  Month 4              No                         No          Yes         No         Yes         No         Yes        Yes
  Month 12             No                         No          No          Yes        No          Yes        Yes        Yes
  \# of patients (%)   213 (72.95)                20 (6.85)   11 (3.77)   1 (0.34)   19 (6.51)   3 (1.03)   1 (0.34)   24 (8.22)

Summary of Immunosuppressive Treatment Regimens {#sec014}
-----------------------------------------------

This section sheds light on information about main immunosuppressive medications that have been considered for this study (tacrolimus, steroid, and sirolimus). As mentioned before, we focus on 292 patients with no prior history of diabetes.

### Tacrolimus {#sec015}

Tacrolimus (Prograf) is the main immunosuppressive drug utilized in this study. [Fig 1](#pone.0142363.g001){ref-type="fig"} (the first three columns) demonstrates the number of patients at month 1, 4, and 12 using tacrolimus, which include 283, 275, and 270 patients (out of 292 patients), respectively. As our primary interest in this study is to analyze the incidence of hyperglycemia, we further classified patients in terms of whether they experienced hyperglycemia at a specific time or not, and [Fig 1](#pone.0142363.g001){ref-type="fig"} reveals this information as well.

![Number of patients who used immunosuppressive drugs at months 1, 4, and 12.\
Such patients are further classified as having hyperglycemia (HG) or not at that specific time points.](pone.0142363.g001){#pone.0142363.g001}

Another important point regarding tacrolimus is the dosage goals and achieved levels at different points of time. Tacrolimus goals are adjusted to avoid toxicity and to the lowest dose possible to avoid rejection per clinical standards of care. This is a standard clinical practice and is based on individual response and pharmacokinetics. [Table 6](#pone.0142363.t006){ref-type="table"} summarizes this information. It should be noted that the achieved levels of tacrolimus are represented in terms of the average trough level of tacrolimus.

10.1371/journal.pone.0142363.t006

###### Tacrolimus goals and achieved levels (average trough level) at months 1, 4, and 12.
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  **Time point**   **Tacrolimus goal**   **Tacrolimus achieved average trough level**
  ---------------- --------------------- ----------------------------------------------
  1 month          10--12 mg/dL          11.88 mg/dL
  4 months         8--10 mg/dL           9.59 mg/dL
  12 months        6--8 mg/dL            7.83 mg/dL

### Steroid {#sec016}

Steroid is the second main immunosuppressive drug incorporated in this study. [Fig 1](#pone.0142363.g001){ref-type="fig"} (the second three columns) illustrates the number of patients at month 1, 4, and 12 using steroid, which include 138, 147, and 140 patients (out of 292 patients), respectively. This shows that in comparison with tacrolimus which was used by the majority of patients, fewer patients used steroid. (According to what explained for tacrolimus, the percentages of patients using tacrolimus at months 1, 4, and 12 were 283/292 = 97%, 275/292 = 94%, and 270/292 = 92%, respectively.) [Fig 1](#pone.0142363.g001){ref-type="fig"} also shows the number of patients who used steroid and experienced hyperglycemia.

Steroid is usually prescribed by the following mechanism. If after using induction steroids (which last for up to 5 days post-transplant) a patient has an organ rejection, she will receive a taper dose of steroid (i.e., slow withdrawal). Then, by 1 month post-transplant, the patient will be put on the maintenance regimen of 5 mg daily (which is a low dosage), unless the patient has another rejection(s) later and needs possibly extra dosage of steroid therapy. To this end, we observed the following from the data set: (1) Among the 292 patients, only 20 patients had organ rejection at month 1, and hence, had to use a taper dose of steroid at this month. Therefore, there remained 272 patients who had no rejection during month 1. (2) Among 20 patients at month 1, 4 patients at month 4 and 1 patient at month 12 experienced organ rejection (these were mutually exclusive patients). (3) Among 272 patients at month 1, 5 patients at month 4 and 6 patients at month 12 experienced organ rejection (these were mutually exclusive patients). Therefore, according to the mechanism explained before, it can be concluded that 4+5+1+6 = 16 patients (out of 292) had increased dose of steroid (i.e., more than 5 mg daily) after 1 month post-transplant. Furthermore, as explained before, according to [Fig 1](#pone.0142363.g001){ref-type="fig"}, 138, 147, and 140 patients used steroid at months 1, 4, and 12, respectively. Therefore, 138-(4+1) = 133, 147-(4+5) = 138, and 140-(1+6) = 133 patients remained on the regimen of 5 mg daily at months 1, 4, and 12, respectively.

### Sirolimus {#sec017}

Sirolimus (Rapamune) is the third main immunosuppressive drug incorporated in this study. [Fig 1](#pone.0142363.g001){ref-type="fig"} shows that sirolimus was utilized by a very small proportion of patients.

Time-Dependent Cox Regression Model: Recurrent Incidence of Hyperglycemia {#sec018}
-------------------------------------------------------------------------

To address events that may occur repeatedly, such as the repeated occurrence of hyperglycemia, we need to incorporate covariates that change over time (e.g., BMI, BP, etc.). To this end, we employed a Cox regression model with time-dependent covariates and recurrent events, where each event is assumed to occur once a patient meets the criteria defined in [Table 5](#pone.0142363.t005){ref-type="table"}. The performance measure in this model is the *hazard ratio* (HR), such that if mean HR ≥ 1, the corresponding covariate will have a positive effect on the response variable (and vice versa).

According to [Table 7](#pone.0142363.t007){ref-type="table"} (Part I), induction immunosuppressive agents (thymoglobulin and simulect) and steroids were significantly associated with lower and higher chance of recurrent hyperglycemia, respectively. However, neither using tacrolimus nor its average trough level was significantly associated with the repeated occurrence of hyperglycemia. Therefore, one cannot establish the diabetogenic effect of tacrolimus when hyperglycemia occurs repeatedly. As we will see in the next section, this finding is in a sharp contrast with the case where only the first incident of hyperglycemia is considered.

10.1371/journal.pone.0142363.t007

###### Effect of immunosuppressive drugs on hyperglycemia: The results of two statistical inference methods (numbers in bold represent statistically significant covariates at 95% confidence level).
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  **Covariates**                                                                                 **Part I: Time-dependent**   **Part II: Time-independent**                                               
  ---------------------------------------------------------------------------------------------- ---------------------------- ------------------------------- ------- ----------- ------- ------- ------- -----------
  Simulect^[c](#t007fn003){ref-type="table-fn"}^ (unadj^[e](#t007fn005){ref-type="table-fn"}^)   0.51                         0.274                           0.953   **0.035**   0.655   0.299   1.437   0.291
  Simulect (adj^[f](#t007fn006){ref-type="table-fn"}^)                                           0.267                        0.131                           0.543   **0.000**   0.444   0.190   1.036   0.060
  Thymoglobulin^[c](#t007fn003){ref-type="table-fn"}^ (unadj)                                    0.68                         0.480                           0.950   **0.025**   0.645   0.401   1.038   0.071
  Thymoglobulin (adj)                                                                            0.658                        0.458                           0.947   **0.024**   0.640   0.388   1.055   0.080
  Avg. *C* ~0~ (unadj)                                                                           0.993                        0.859                           1.147   0.924       1.949   1.793   2.120   **0.000**
  Avg. *C* ~0~ (adj)                                                                             0.992                        0.859                           1.146   0.912       1.982   1.788   2.197   **0.000**
  Tacrolimus^[d](#t007fn004){ref-type="table-fn"}^ (unadj)                                       0.922                        0.434                           1.963   0.834       1.285   0.470   3.512   0.625
  Tacrolimus (adj)                                                                               0.689                        0.297                           1.601   0.387       1.156   0.397   3.370   0.790
  Sirolimus^[d](#t007fn004){ref-type="table-fn"}^ (unadj)                                        1.329                        0.655                           2.694   0.431       0.834   0.305   2.279   0.723
  Sirolimus (adj)                                                                                1.786                        0.852                           3.745   0.124       0.810   0.280   2.344   0.697
  Steroid^[d](#t007fn004){ref-type="table-fn"}^ (unadj)                                          1.230                        0.894                           1.691   0.204       1.248   0.803   1.939   0.325
  Steroid (adj)                                                                                  1.562                        1.131                           2.158   **0.007**   1.441   0.900   2.305   0.128

^a^ 95% confidence interval,

^b^ P-values are obtained based on standard Normal distribution,

^c^ An immunosuppressive agent: Induction therapy,

^d^ An immunosuppressive agent: Maintenance therapy,

^e^ Unadjusted (univariate) analysis,

^f^ All adjusted analyses were done based on age, race, gender, BMI, BP, Chol, HDL, LDL, UA, and TG.

Time-Independent Cox Regression Model: First Incidence of Hyperglycemia {#sec019}
-----------------------------------------------------------------------

The reason that the diabetogenic effect of tacrolimus cannot be established when hyperglycemia is occurring repeatedly may be due to the fact that tacrolimus dosage is usually reduced with the passage of time after transplant (see [Table 6](#pone.0142363.t006){ref-type="table"}). To test this hypothesis, we analyzed the immunosuppressive effect when hyperglycemia happens for the first time. We used a time-independent Cox regression model, in which only covariates at the time of first occurrence are considered. According to [Table 7](#pone.0142363.t007){ref-type="table"} (Part II), the average trough level of tacrolimus is significantly associated with a higher chance of first hyperglycemia incident, which implies that the diabetogenic effect of tacrolimus can be established in this case. This observation highlights the importance of differentiating between the first and recurrent incidents of hyperglycemia.

As other observations made in this regard, induction immunosuppressive agents (thymoglobulin and simulect) are significantly associated with lower chance of first hyperglycemia. However, we cannot establish any significant association between using steroid and the first incidence of hyperglycemia. This can be due to the fact that high dosages of steroid were only considered for a small proportion of patients in month 1 post-transplant (see section "Summary of Immunosuppressive Treatment Regimens" for more information).

Kaplan-Meier Analysis: Hyperglycemia Incidence {#sec020}
----------------------------------------------

The results of time-independent analysis established by the Cox regression model shows the significant association between the average trough level of tacrolimus and the first incidence of hyperglycemia. Here, we aim to use *Kaplan-Meier survival analysis* to calculate the probability of having hyperglycemia obtained from Kaplan-Meier survival curves.

To this end, we consider the main *stratum* based on average trough level of tacrolimus classified as "≤10" and "\>10" mg/dL. In order to fully comprehend the effect of these levels on the incidence of hyperglycemia, we conduct unadjusted (univariate) analysis as well as ten adjusted analyses for those risk factors mentioned before. However, to incorporate these risk factors into the Kaplan-Meier survival analysis, they should be discretized in classes, which are shown in [Table 8](#pone.0142363.t008){ref-type="table"}. It should be noted that the classification thresholds for each of these risk factors have been set so as to distinguish the groups in terms of health-related risks (e.g., BMI of 30 kg/m^2^ for obesity). Furthermore, except age, gender, race, and blood pressure, other thresholds have been obtained from \[[@pone.0142363.ref070]\]. Regarding the blood pressure, if the systolic and diastolic blood pressure are "\<120" and "\<80" mm Hg, respectively, the patient is normal. Otherwise, the patient has hypertension. These thresholds have been obtained from \[[@pone.0142363.ref071]\].

10.1371/journal.pone.0142363.t008

###### Description of groups formed by risk factors.
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  **Risk Factors**   **Unit**   **Group 0**        **Group 1**
  ------------------ ---------- ------------------ --------------
  Age                Years      \<50               ≥ 50
  Gender             ---        Female             Male
  Race               ---        White              non-White
  BMI                kg/m^2^    \<30 (non-obese)   ≥30 (obese)
  BP                 ---        Normal             Hypertension
  Chol               mg/dL      \<200              ≥200
  HDL                mg/dL      ≥40                \<40
  LDL                mg/dL      \<130              ≥130
  TG                 mg/dL      \<150              ≥150
  UA                 mg/dL      \<7.3              ≥7.3

[Fig 2](#pone.0142363.g002){ref-type="fig"} presents the above-mentioned survival curves. For simplicity, patients with an average tacrolimus trough level of less than or equal to (more than) 10 mg/dL are said to have *Trough-level 0 (1)*. [Fig 2A](#pone.0142363.g002){ref-type="fig"} shows that Trough-level 1 patients have significantly higher chance of experiencing hyperglycemia (HG) than Trough-level 0 patients (i.e., Logrank *P* \<0.0001). Specifically, almost all of the former group experience HG by month 4 (i.e., probability of experiencing HG ≈ 100%), while the latter group still have about 80% chance of not experiencing HG by year 1. Although we made these observations for the unadjusted (univariate) analysis, the same behavior can be seen for adjusted analyses: the chance of experiencing HG is significantly different (i.e., Logrank *P* \<0.0001) across groups formed by different risk factors (see [Fig 2B](#pone.0142363.g002){ref-type="fig"}--[2K](#pone.0142363.g002){ref-type="fig"}). Furthermore, Trough-level 1 patients with any of the following conditions almost certainly experience HG by month 1: non-White ethnicity, obese (BMI \>30 kg/m^2^), and LDL ≥130 mg/dL. Moreover, Trough-level 1 patients with any of the following conditions experience HG by month 1 with a chance not less than 90%: age\>50, male, hypertension, Chol ≥200 mg/dL, HDL \<40 mg/dL, UA ≥7.3 mg/dL, or TG ≥150 mg/dL.

![Kaplan-Meier survival curves: Cumulative probability of experiencing hyperglycemia (%) as a result of having different average trough levels of tacrolimus: ≤10 mg/dL vs. \>10 mg/dL. In all parts (A)-(K), the *P*-value by the Logrank test is \<0.0001. (+ represents censored events.).\
(A) Unadjusted (univariate) analysis. (B) Adjusted analysis with age. (C) Adjusted analysis with race. (D) Adjusted analysis with gender. (E) Adjusted analysis with BMI. (F) Adjusted analysis with BP. (G) Adjusted analysis with Chol. (H) Adjusted analysis with HDL. (I) Adjusted analysis with LDL. (J) Adjusted analysis with UA. (K) Adjusted analysis with TG.](pone.0142363.g002){#pone.0142363.g002}

Other Risk Factors for the Incidence of Hyperglycemia {#sec021}
-----------------------------------------------------

We also analyzed the associations of other well-known risk factors for both the first and recurrent incidence of hyperglycemia. To this end, we again applied two types of Cox regression model. The results of these analyses are provided in [Table 9](#pone.0142363.t009){ref-type="table"}. We found that age and HDL were significantly associated with the first incident of hyperglycemia, whereas age, race (non-White), BMI, HDL, and UA were significant risk factors for the recurrent incidence of hyperglycemia.

10.1371/journal.pone.0142363.t009

###### Risk factors that affect the incidence of hyperglycemia.
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  **Risk Factors**                                        **Part I: Time-dependent**   **Part II: Time-independent**                                               
  ------------------------------------------------------- ---------------------------- ------------------------------- ------- ----------- ------- ------- ------- -----------
  Age                                                     1.044                        1.031                           1.056   **0.000**   1.022   1.004   1.040   **0.018**
  Race: Non-White^[c](#t009fn003){ref-type="table-fn"}^   1.769                        1.234                           2.536   **0.002**   1.195   0.707   2.019   0.506
  Gender: Male                                            1.108                        0.738                           1.661   0.621       1.105   0.658   1.854   0.706
  BMI                                                     1.048                        1.017                           1.079   **0.002**   0.976   0.932   1.023   0.314
  BP                                                      1.001                        0.987                           1.015   0.903       0.996   0.979   1.014   0.672
  Chol                                                    1.001                        0.995                           1.008   0.699       1.007   0.998   1.015   0.133
  HDL                                                     0.976                        0.960                           0.992   **0.003**   0.972   0.950   0.993   **0.010**
  LDL                                                     0.995                        0.987                           1.003   0.204       0.997   0.986   1.007   0.509
  UA                                                      0.833                        0.722                           0.961   **0.012**   0.829   0.680   1.010   0.063
  TG                                                      1.002                        1.000                           1.004   0.145       1.002   0.999   1.004   0.206

^a^ 95% confidence interval,

^b^ P-values are obtained based on standard Normal distribution,

^c^ Including Native American, Hispanic, and Black.

Combining these results with those in [Table 7](#pone.0142363.t007){ref-type="table"}, it can be stated that the first incidence of hyperglycemia is more attributed to the diabetogenic effect of tacrolimus. However, in the absence of such an effect, the recurrent incidence of hyperglycemia is mainly imputed to other risk factors (e.g., age, race (non-White), BMI, HDL, and UA). A review of Tables [7](#pone.0142363.t007){ref-type="table"} and [9](#pone.0142363.t009){ref-type="table"} also shows potential consequences of choosing the right statistical tool in determining the diabetogenic effect of immunosuppressive drugs or corresponding risk factors for hyperglycemia incidence. In addition, observing that the first and recurrent types of hyperglycemia are subject to different risk factors might have broader implications for other similar chronic diseases. The current literature largely overlooks time-dependent analyses, and our results shed light on the importance of closing this gap.

Impact of the Inpatient Period {#sec022}
------------------------------

Prior studies have addressed the importance of the inpatient period: what happens to patients during post-transplant hospitalization may have an impact on patient's conditions after hospital discharge \[[@pone.0142363.ref067], [@pone.0142363.ref068]\]. To evaluate the impact of inpatient period, we analyzed the effect of (1) average bed glucose result (bed.avg), which is obtained by a poke test, (2) average blood glucose result (blood.avg), and (3) inpatient hyperglycemia (in.hyp) on the incidence of hyperglycemia. [Table 10](#pone.0142363.t010){ref-type="table"} summarizes the results obtained from our statistical methods. Based on [Table 10](#pone.0142363.t010){ref-type="table"}, the average bed and blood glucose results are significantly associated with both the first and the recurrent incidence of hyperglycemia. However, the occurrence of inpatient hyperglycemia is only associated with recurrent incidence of hyperglycemia.

10.1371/journal.pone.0142363.t010

###### Effect of inpatient period on hyperglycemia incidence.

![](pone.0142363.t010){#pone.0142363.t010g}

  **Inpatient Parameters**                                                                      **Part I: Time-dependent**   **Part II: Time-independent**                                               
  --------------------------------------------------------------------------------------------- ---------------------------- ------------------------------- ------- ----------- ------- ------- ------- -----------
  bed.avg^[e](#t010fn005){ref-type="table-fn"}^ (unadj^[c](#t010fn003){ref-type="table-fn"}^)   1.029                        1.024                           1.035   **0.000**   1.023   1.013   1.032   **0.000**
  bed.avg (adj^[d](#t010fn004){ref-type="table-fn"}^)                                           1.024                        1.018                           1.030   **0.000**   1.018   1.008   1.029   **0.000**
  blood.avg^[f](#t010fn006){ref-type="table-fn"}^ (unadj)                                       1.031                        1.023                           1.038   **0.000**   1.022   1.011   1.033   **0.000**
  blood.avg (adj)                                                                               1.024                        1.016                           1.032   **0.000**   1.018   1.007   1.030   **0.002**
  in.hyp^[g](#t010fn007){ref-type="table-fn"}^ (unadj)                                          3.509                        1.557                           7.908   **0.002**   2.162   0.874   5.347   0.095
  in.hyp (adj)                                                                                  2.496                        1.080                           5.768   **0.032**   1.543   0.613   3.885   0.358

^a^ 95% confidence interval,

^b^ P-values are obtained based on standard Normal distribution,

^c^ Unadjusted (univariate) analysis,

^d^ All adjusted analyses were done based on age, race, gender, BMI, BP, Chol, HDL, LDL, UA, and TG,

^e^ Average bed glucose result,

^f^ Average blood glucose result,

^g^ Inpatient hyperglycemia.

Discussion {#sec023}
==========

Our analyses highlight the complex nature of post-renal transplant hyperglycemia. Some patients never exhibit hyperglycemia, some develop permanent hyperglycemia (NODAT), while for others hyperglycemia may be transient or even recurrent. Hyperglycemia and NODAT have been mostly analyzed for a short period after transplantation \[[@pone.0142363.ref072], [@pone.0142363.ref073]\]. However, their incidence may be underestimated by such short-term studies (see \[[@pone.0142363.ref074]--[@pone.0142363.ref079]\] for some studies analyzing long-term analyses). Our results show that if the diabetogenic effect of immunosuppressive drugs is of interest, short-term analyses might be preferred, while long-term analyses are more suitable when studying other risk factors.

The idea of analyzing hyperglycemia from this perspective (i.e., time course of complications) can also be extended to other chronic diseases in which both the first incident and the recurrent ones need to be monitored. For example, prostate cancer and breast cancer are among diseases that may show signs only once or may do so from time to time with periods of remission in between \[[@pone.0142363.ref080], [@pone.0142363.ref081]\]. For this category of diseases, considering both time-dependent and time-independent analyses (as we did in this study) may provide new and important insights.

There are some limitations in our study. First, due to the nature of our study, having patients' information on a more regular basis (e.g., monthly) would improve the accuracy of our results. Second, if the data set included patients' information after the first year post-transplant, we would be able to conduct a more robust Cox regression and Kaplan-Meier survival analysis. Third, although, according to [Table 5](#pone.0142363.t005){ref-type="table"}, 79 patients (who experienced post-transplant hyperglycemia for the first time) are sufficient for the purpose of our analyses, it might be a relatively small sample. Finally, even though sirolimus and steroid were used for the minority of patients (in comparison with tacrolimus), we had no information about the exact dosages and trough levels of these two drugs. Otherwise, we could also evaluate the possible association between their trough levels and incidence of hyperglycemia.

Finally, some of our findings may not be generalizable to other types of solid organ transplants (e.g., heart, liver, and pancreas). Therefore, testing our findings can be a fruitful path for future research. By extending the idea of this study and incorporating the time course of complications for other organs, one can establish a holistic framework to analyze (a) the diabetogenic effect of immunosuppressive drugs, and (b) the effect of other risk factors.

Conclusion {#sec024}
==========

We analyzed the effects of (1) immunosuppressive drugs, (2) risk factors, and (3) inpatient hyperglycemia on the first and recurrent incidence of post-transplant hyperglycemia in patients who had no history of diabetes mellitus prior to their transplants. We employed two statistical inference methods: (1) Cox regression model with time-dependent covariates to analyze hyperglycemia with recurrence and (2) Cox regression model with time-independent covariates to evaluate the first incidence of hyperglycemia. We also employed Kaplan-Meier survival analysis to characterize the cumulative probability of experiencing post-transplant hyperglycemia over time.

Based on the results obtained from these methods, we can state that the diabetogenic effect of tacrolimus (based on its trough level) can be established when hyperglycemia is experienced for the first time. However, in a sharp contrast, this effect cannot be established for the recurrent incidents of hyperglycemia. This difference might be due to the fact that tacrolimus dosage is reduced by physicians over time. As the diabetogenic effect is ruled out, our results show that age, race (non-White), BMI, HDL, steroid use, and uric acid are the only significant risk factors for the recurrent incidence.
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